We recommend the use of animal models and patient-derived xenografts (PDXs) to evaluate the functional impact of KCNJ2 modulation on ccRCC progression, metastasis, and response to therapy. This evidence concerns the gene KCNJ2 and nonpapillary renal cell carcinoma.